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INFECTION – Cost Studies
PIN25
PublIC ANd PrIvATE PAyEr PErSPECTIvES ON ThE NET COST OF 
ImPlEmENTATION OF 13-vAlENT PNEumOCOCCAl CONjugATE vACCINE 
(PCv13) COmPArEd WITh 7-vAlENT PNEumOCOCCAl CONjugATE vACCINE 
(PCv7) TO IN ThE uNITEd STATES
Kohli M.1, Maschio M.1, Farkouh R.A.2, McGarry L.3, Strutton D.R.2, Weinstein M.C.4
1Optum, Burlington, ON, Canada, 2Pfizer, Inc., Collegeville, PA, USA, 3Optum, Cambridge, MA, 
USA, 4Harvard School of Public Health, Boston, MA, USA
Objectives: In 2010, the US Advisory Committee on Immunization Practices recom-
mended 7-valent pneumococcal conjugate vaccine (PCV7) be replaced by 13-valent 
vaccine (PCV13) for routine use in a four-dose series at 2, 4, 6, and 12-15 months of 
age. Published analyses estimated that PCV13 implementation would be cost-saving 
in aggregate, but the net economic impact on particular payers is unknown. We 
disaggregated the expected costs and savings by payer to determine the net costs for 
public and private payers over a 10-year horizon. MethOds: A Markov model was 
used to simulate vaccination and pneumococcal disease events and their related 
costs with PCV13 compared to PCV7 from 2010 to 2019. The PCV13 strategy included 
a one-time catch-up dose in 2010 for children who had completed the PCV7 series. 
Disease reductions both in vaccinated and other age groups were modeled based 
on PCV7 efficacy and effectiveness data. Medical costs related to pneumococcal 
disease were allocated to public (Medicare; Medicaid; military) or private payers 
using age-specific health care insurance coverage survey data. Vaccine program 
costs were allocated based on sales data. All costs were measured in 2013 US dol-
lars. Results: In the simulation, 40.3 million(M) children participated in routine 
vaccination while 5.8M received a catch-up dose in the PCV13 strategy. The PCV13 
strategy prevented an additional 121,300 cases of invasive pneumococcal disease, 
3.3M of pneumonia and 17.6M of acute otitis media compared to PCV7 over 10 years. 
Public and private payers will pay $3.5 billion(B) and $2.6B, respectively, for the vac-
cine but accrue $6.1B and $4.2B in overall savings. While the magnitude of savings 
varied in sensitivity analyses, implementation of PCV13 remained cost-saving for 
all payers. cOnclusiOns: The currently-recommended PCV13 pediatric program 
is cost-saving for both public and private payers. Net savings were greater for public 
payers, despite higher vaccine costs.
PIN26
budgET ImPACT ANAlySIS OF dOluTEgrAvIr IN ThE TrEATmENT OF humAN 
ImmuNOdEFICIENCy vIruS (hIv) IN ONTArIO, CANAdA
Monga N.1, Cui Q.1, Maschio M.2, Becker D.L.2, de los Rios P.3, Ismaila A.4
1GlaxoSmithKline, Mississauga, ON, Canada, 2OptumInsight, Burlington, ON, Canada, 3ViiV 
Healthcare, Laval, QC, Canada, 4GlaxoSmithKline, Research Triangle Park, NC, USA
Objectives: To estimate the budgetary impact of adding dolutegravir to the Ontario 
Drug Benefit Formulary (ODBF) for a three-year period for the treatment of HIV 
infection in adults and children (≥ 12 years of age). MethOds: Three discrete popu-
lations were considered: treatment-naïve (TN) patients staying on their first line, 
TN switchers (assumed switches within the first 6 months of antiretroviral therapy 
(ART) initiation) and treatment-experienced (TE) patients. Epidemiology data were 
obtained from published sources. Ontario-specific data and analysis from the IMS 
Brogan Database were used to estimate the proportion of patients who were treated 
and covered by the ODBF, proportions of patients remaining on their first regi-
men after ART initiation over time, comparators and historical market share data. 
ART drug costs were calculated based on the dosage of each regimen component 
from the respective product monographs and unit costs from the ODBF. The budget 
impact was calculated for the whole HIV population and separately for each popula-
tion. Sensitivity analyses were conducted on five key input parameters. Results: 
Out of the 12 comparators, dolutegravir-containing regimens were assumed to take 
market shares from 6 regimens: Atripla, Truvada⁄Prezista⁄Norvir, Truvada⁄Isentress, 
Truvada⁄Reyataz⁄Norvir, Kivexa⁄Isentress and Stribild. Adding dolutegravir to the list 
of reimbursed ARTs on the ODBF will result in incremental savings in each of the 
three years following the listing date of $2,717,585, $5,181,704, and $8,040,076 for a 
total savings of $15,939,365. The analysis was somewhat sensitive to assumptions 
made regarding HIV incidence and prevalence and the proportion treated with drug 
benefits. Based on the accuracy of the assumptions made in this analysis, the total 
savings to the budget over a three-year period may range between $12,751,492 and 
$19,127,238. cOnclusiOns: The addition of adding dolutegravir to the ODBF will 
result in a significant net savings through the displacement of more expensive 
regimens in Ontario.
PIN27
‘dE-ESCAlATION’ uSINg mICAFuNgIN FOr ThE TrEATmENT OF SySTEmIC 
CANdIdA INFECTION: budgET ImPACT IN FrANCE ANd gErmANy
Casamayor M.1, Van Engen A.2, Musingarimi P.3, Odeyemi I.A.3, Odufowora-Sita O.3, Watt M.3
1Quintiles, Barcelona, Spain, 2Quintiles, Hoofddorp, The Netherlands, 3Astellas Pharma Europe 
Ltd, Chertsey, UK
Objectives: The prevalence of systemic Candida infection (SCI) caused by non-albi-
cans species, which display greater resistance to azole antifungal agents, is increas-
ing. Treatment with broad-spectrum antifungal agents, such as echinocandins, with 
subsequent switch to fluconazole if isolates are shown to be sensitive (‘de-escala-
tion’) is recommended by treatment guidelines. We developed a model to assess the 
budget impact of the de-escalation strategy in France and Germany. MethOds: The 
budget impact of initial micafungin treatment in a de-escalation strategy versus 
fluconazole in an escalation strategy was modelled using decision analysis based on 
data from relevant studies and a cost-effectiveness analysis. Duration of appropriate 
treatment was 14 days, meaning that treatment outcome was assessed after 14 days, 
or 17 days if fluconazole had to be switched once fluconazole sensitivity was known 
(after 3 days of therapy). Clinical success was defined as resolution or reduction of all 
signs, symptoms and radiographic abnormalities associated with SCI at treatment 
end. Results: In France and Germany, the incidence of SCI was estimated at 28 
Objectives: Azithromycin has an attractive safety profile in treating or preventing 
certain bacterial infections. However, there is growing concern that Azithromycin 
may be associated with increased cardiovascular risk and lead to cardiovascu-
lar death in high risk patients. We therefore conducted a meta-analysis of rand-
omized Controlled trials to describe the cardiovascular risk profile of those patients 
receiving Azithromycin. MethOds: The MEDLINE and Cochrane Central Register 
of Controlled Trials databases were searched from 1991 to September 2013 using 
specific search terms for English-language trials of comparing high baseline risk 
of cardiovascular disease patients receiving Azithromycin or placebo and have 
reported cardiovascular outcomes. Abstracts from major scientific meetings were 
also reviewed.In the analysis, Methods based on odds ratios (ORs) was used. OR was 
calculated using a random-effects model (because we assume that the treatment 
effect in all the included studies are not identical) from the ORs and 95% confidence 
intervals (CIs) were used for each end point in each study. Statistical heteroge-
neity scores were assessed with an I42test. Sensitivity analyses were performed 
by removing some trials and recalculating the combined ORs for the remaining 
studies. Results: 12 trials randomized a total of 15,588 patients into two groups, 
treatment and placebo. Treatment effect on any cardiovascular outcome was not sig-
nificantly different in any of the nine trials. For all trials combined, the pooled odds 
ratio for mortality was not significantly different [(OR, 0.873; 95% CI, 0.743–1.027), p 
= 0.102]. No heterogeneity was observed (I2= 0). Similarly, there was no difference 
in the pooled odds ratio for hospitalization and coronary intervention [(OR, 1.021; 
95% CI, 0.882–1.182), p = 0.774, I2= 0%] and [(OR, 0.998; 95% CI, 0.885–1.125), p = 0.982, 
I2= 0%], respectively. cOnclusiOns: The findings of this systematic review suggest 
that no significant relationships exist between Azithromycin and risk of cardiovas-
cular events in high risk patients.
PIN23
ANTImICrObIAlS: A mAjOr ClASS OF drugS CAuSINg AdvErSE drug 
rEACTIONS IN ThE ICuS OF AN INdIAN PublIC TEAChINg hOSPITAl
Kandukuri P.1, Tiwari P.2, Gombar S.3, D’cruz S.3, Sachdev A.3
1National Institute of Pharmaceutical Education and Research, Mohali, India, 2National Institute 
of Pharmaceutical Education and Research (NIPER), S.A.S Nagar, India, 3Government Medical 
College and Hospital, Chandigarh, India
Objectives: Patients in the intensive care unit (ICU) have multiorgan dysfunction 
as well as altered pharmacokinetic parameters. Hence, they are more susceptible to 
adverse drug reactions (ADRs). The objective of the study was to identify the major 
class of drugs involved in causing ADRs in ICU patients of an Indian public teaching, 
tertiary care hospital. MethOds: A prospective observational study was conducted 
in the ICUs of a public teaching hospital. All the relevant data was collected from 
the patients case records in a standard data collection format and the patients 
were followed until discharge or transferred from the ICUs. ADRs were identified 
based on the subjective findings, objective findings and spontaneous reporting. The 
drugs responsible for causing ADR were identified and classified using Anatomic, 
Therapeutic and Chemical(ATC) classification. Results: The results of this 12 week 
study were based upon the data obtained from 70 patients(37 males, 33 females). 
Only 10 patients developed ADRs. The drugs causing ADRs were classified using the 
ATC classification. This showed that the most common ADR causing drugs belonged 
to the class of infections and infestations (30%), cardiovascular system(14%), endo-
crine system(14%), respiratory system (14%) and others (14%), followed by Brain 
and nervous system (7%), blood and blood forming agents (7%) accounting for least 
number of ADRs. cOnclusiOns: In this pilot study, Antimicrobials was found to 
be the most common class of drugs causing ADRs. We studied small number of 
patients, it is suggested that future large scale studies should be done to further 
gain insight into the ADRs.
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hIghEr Cd4 AT ArT INITIATION PrEdICTS grEATEr lONg TErm lIkElIhOOd 
OF Cd4 NOrmAlIzATION
Palella F.J1, Armon C.2, Chmiel J.S.1, Brooks J.T.3, Debes R.4, Novak R.M.5, Yangco B.G.6, Wood K.2, 
Durham M.3, Buchacz K.3
1Northwestern University Feinberg School of Medicine, Chicago, IL, USA, 2Cerner Corporation, 
Vienna, VA, USA, 3Centers for disease Control and Prevention, Atlanta, GA, USA, 4Cerner 
Corporation, North Kansas City, MO, USA, 5University of Illinois at Chicago, Chicago, IL, USA, 
6Infectious disease Research Institute, Tampa, FL, USA
Objectives: Higher plasma CD4 cell counts per mm3 at ART initiation (AI-CD4) 
improve long-term CD4 responses and survival. Recent data suggest CD4 > 750 is a 
clinically significant threshold for AIDS-related illness reduction and immune “nor-
malization”. We evaluated the effect of AI-CD4 on achieving CD4 > 750 and mortality 
risk. MethOds: Among HIV Outpatient Study patients seen during 1996-2012 for 
three or more years after AI, we analyzed CD4 trajectories and mortality rates per 
100 persons-years (MR) by AI-CD4, and the association of AI-CD4 with achieving CD4 
> 750 (“normalization”) using Kaplan-Meier methods and Cox proportional hazards 
models. Results: Of 1327 eligible patients followed a median of 7.9 years, > 85% 
received HAART ≥ 75% of follow-up time, and 64 died. Higher AI-CD4 was associated 
with increased median peak CD4 (p < 0.001). Maximal CD4 response and benefit 
plateaued at eight years, but differences by AI-CD4 persisted (p < 0.001). Lower 
crude MRs (p = 0.005) and higher CD4 closest to death (p = 0.013) were associated 
with higher AI-CD4. Increases in median CD4 for persons with AI-CD4 < 50 and 
50-199 converged by eight years (< 50% achieved CD4 > 750) whereas patients with 
AI-CD4 > 350 normalized by eight years (> 80% of patients). In multivariable analy-
ses, higher AI-CD4 was the only factor independently associated with achieving 
CD4 normalization during follow-up. cOnclusiOns: Progressively higher AI-CD4 
predicted greater long-term CD4 gains, achieving CD4 normalization, increased 
crude survival rates, and higher CD4 at death. CD4 gains and chances of reaching 
CD4 normalization peaked at eight years after AI. Most with AI-CD4 > 350 eventually 
achieved CD4 normalization while less than half with AI-CD4s < 50 and 50-199 did. 
AI-CD4 ≥ 500 optimized the likelihood of CD4 normalization confirming the hazards 
of delayed and support AI at CD4 ≥ 500.
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diseases are a public health priority in Colombia. The aim of this study was to 
estimate the difference of cases and costs from serotype coverage of pneumococ-
cal conjugated vaccines of 10 and 13 serotypes (PCV10 and PCV13, respectively) in 
population under 5 years old in Colombia. MethOds: A deterministic model was 
built for a cohort of children born in 2011. The probabilities of incidence, mortality 
and sequelae of pneumonia, meningitis, sepsis, and acute otitis media and clinical 
effectiveness of PCV10 and PCV13 for this population, were determined through a 
systematic literature review. Vaccination scheme 2+1 was included, herd effect of 
42% and population coverage of 84.09% was assumed for both vaccines. The differ-
ences between the evaluated vaccines were estimated in terms of opportunity costs 
and net profit. The study was conducted from the perspective of third-party payers 
and a time horizon of 5 years. Costs were expressed in 2012 USD (exchange rate 
US$1 = $1798.23 COP). Results: A cohort of 652,611 children was assumed. Model 
showed a higher protection with PCV13 in comparison to PCV10. With PCV13 a dif-
ference of 98 prevented deaths for meningitis, pneumonia and sepsis was observed. 
The opportunity cost of having used PCV10 instead of PCV13 was US$20,090,913 in 
the 5 year follow-up (US$4,018,183 per year). Costs related to disease not covered 
by PCV10 are between an annual average of US$4,087,138 to $4,373,597; 82% due to 
lost productivity associated with premature death, 12% to cases of disease and a 
lower percentage to sequelae. cOnclusiOns: PCV13 prevents a greater number 
of deaths and consequences associated with pneumococcal infection compared 
to PCV10, resulting in a considerable economic impact measured in number of 
productive years for Colombia.
PIN31
ECONOmIC EvAluATION OF FIdAxOmICIN COmPArEd WITh vANCOmyCIN IN 
ThE TrEATmENT OF ClOSTrIdIum dIFFICIlE INFECTION
McCrea C1, Perera S.1, Van Engen A.2, Watt M.3, Nazir J.3
1HERON Evidence development, London, UK, 2Quintiles Consulting, Hoofddorp, The Netherlands, 
3Astellas Pharma Europe Ltd, Chertsey, UK
Objectives: Two Phase 3 clinical trials in patients with Clostridium difficileinfection 
(CDI) showed fidaxomicin to be non-inferior to vancomycin in terms of clinical 
cure, but superior in terms of recurrence. In a pooled, modified intention-to-treat 
analysis of 962 patients, recurrence rates at 28 days were 26.0% (vancomycin), and 
14.1% (fidaxomicin) (p< 0.001) [Crook, et al, 2012]. This analysis aimed to evaluate 
the cost-effectiveness and budget impact of fidaxomicin compared with vanco-
mycin from the perspective of the National Health Service in England. MethOds: 
A Markov model was developed with 10-day cycle length, capturing clinical cure, 
first and subsequent recurrence, and treatment outcomes within 1-year. Six patient 
sub-groups were analysed: patients with (a) severe CDI; (b) a first recurrence; (c) 
cancer; (d) aged ≥ 65 years; (e) renal impairment; and (f) receiving concomitant 
antibiotics. Model inputs were derived from published literature and an expert 
panel. Results: Total costs per patient were lower with fidaxomicin than vanco-
mycin for recurrent CDI (£16 535 vs. £16 926), cancer patients (£14 430 vs. £15 373) 
and patients aged ≥ 65 (£14 062 vs. £14 715). Fidaxomicin was associated with higher 
quality-adjusted life years (QALYs) than vancomycin for all patient groups and was 
a dominant option for these three sub-groups. Fidaxomicin was cost-effective at an 
implicit incremental cost-effectiveness ratio (ICER) threshold of £20 000 per QALY 
gained for severe CDI (ICER = £16 529) and patients with renal impairment (ICER 
= £16 693). The annual budget impact of fidaxomicin compared with vancomycin 
would be a saving of approximately £2 500 per patient for the six patient sub-groups 
combined. cOnclusiOns: Fidaxomicin is likely to be a dominant treatment option, 
when compared to vancomycin, for patients with recurrent CDI, cancer or those 
aged ≥ 65, and is likely to be cost-effective at a £20 000 threshold for severe CDI and 
patients with renal impairment.
PIN32
FINANCIAl ANAlySIS OF A vACCINATION CAmPAIgN uSINg 13 vAlENT 
PNEumOCOCCAl CONjugATEd vACCINE (PCv13) WITh EmPlOyErS
Ferreira C.N., Manfrin D.F., Rufino C.S.
Pfizer, Inc., São Paulo, Brazil
Objectives: This study evaluates the ROI (return on investment) for a PCV13 
vaccination with campaign by corporations for individuals who are 50+ years 
old. MethOds: A budget impact analysis was developed considering vaccination 
costs, pneumococcal disease events, and productivity loss from employee absence 
due to sickness or death. Clinical events were calculated using a Markov model 
with individual-level simulation considering a cohort of 1.000 employees and an 
annual discount rate of 5%.Only the portion of employees more than 50 years of age 
was considered. (21% according to Brazilian Institute for Geography and Statistics, 
IBGE). Absence days due to health events were retrieved from national labor leg-
islations. Average wage was retrieved from IBGE 2013. Return on Investment was 
calculated as the time until savings from the cost of productivity gains exceeds 
investment in a vaccination program. Results: A campaign for 206 employees 
50+ years old cost BRL 31.724 and in the first 2 years the return will be BRL 15.449 
due to reduction in events and absenteeism and one fewer death. The ROI will be in 
4,17 years. cOnclusiOns: In addition to decreasing productivity loss, death, and 
additional treatment cost, a pneumococcal vaccination campaign for employees 
over 50 years old yields a positive return on investment.
PIN33
TOTAl hOSPITAlIzATION COST ANd lENgTh OF hOSPITAl STAy FOr 
PATIENTS WITh CArbAPENEm-rESISTANT vErSuS CArbAPENEm-SENSITIvE 
INFECTIONS IN A TErTIAry CArE hOSPITAl
Priyendu A.1, Nagappa A.N.2, Varma M.3, K E V.3, Balakrishnan R.4
1Manipal University, MCOPS, Manipal, India, 2department of Pharmacy Management, Manipal 
College of Pharmaceutical Sciences, Manipal University, Manipal, India, 3Manipal University, 
Manipal, India, 4University of Michigan, MI, MI, USA
Objectives: To find out the average cost of hospitalization and length of hospital 
stay for patients infected with carbapenem-resistant bacteria and compare it with 
and 38/100,000 population/year, respectively. In both countries, the most common 
isolates were C. albicans, C. parapsilosis and C. glabrata. In patients with fluconazole-
resistant isolates, de-escalation resulted in higher cure and survival rates than 
escalation, with cost savings of € 6,880/patient treated in France and € 2,007/patient 
treated in Germany. Regardless of fluconazole sensitivity, de-escalation resulted 
in higher rates of cure and survival than escalation; these benefits were associ-
ated with an additional cost of € 687 and € 1,237 per patient treated in France and 
Germany, respectively. cOnclusiOns: Across all patient groups, de-escalation from 
micafungin improved clinical outcome and survival. This was particularly marked 
in patients with fluconazole-resistant SCI, in whom de-escalation from micafungin 
was cost-saving. Increased costs with de-escalation in the overall population are 
limited and offset by improvement in survival using this strategy.
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budgETAry ImPACT TO A uNITEd STATES hEAlTh PlAN OF AdOPTINg 
SImEPrEvIr (Smv) IN COmbINATION WITh PEgINTErFErON AlFA+rIbAvIrIN 
(Pr) FOr ThE TrEATmENT OF gENOTyPE 1 (g1) ChrONIC hEPATITIS C (ChC) 
INFECTION
Forlenza J.B1, van de Wetering G.2, Treur M.2, Cerri K.3, LaMori J.4, Tandon N.1
1Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 2Pharmerit International, Rotterdam, The 
Netherlands, 3Janssen Pharmaceutica NV, Beerse, Belgium, 4Janssen Scientific Affairs, LLC, 
Raritan, NJ, USA
Objectives: Economic evaluations of CHC therapies may be important from health 
plans’ perspectives. MethOds: A budget impact model compared annual CHC ther-
apy cost before and after SMV+PR adoption for a hypothetical 1,000,000 member 
plan. The proportion treated for CHC was derived from various publications. Base 
case analyses assumed Current state market share (MS) within treatment-naïve 
and -experienced populations was equally allocated between telaprevir+PR and 
boceprevir+PR while SMV+PR MS was 0%; Future MS was 45%, 45%, and 10%, respec-
tively. CHC therapy costs were estimated based on dosing and administration data 
from US prescribing information and 12/2013 wholesale acquisition costs (assumed 
82 kg person). Population allocation by prior response, disease severity, and treat-
ment duration used trials data. Drug-only costs per member per month (PMPM) and 
per treated CHC member (PTM) were estimated. Sustained virologic response (SVR) 
absolute values from trials were used to report annual cost per SVR. Results: The 
model suggested 234 G1 CHC members treated annually. Total health plan’s budget 
(drug-only costs) was estimated at $1.82 PMPM before and after SMV+PR adoption 
(incremental cost -$0.001 PMPM). Annual total costs were $93,311 PTM in Current 
state and $93,271 PTM in Future (incremental cost -$40 PTM). The model calculated 
the health plan’s annual cost per SVR as $147,105 in Current state and $144,261 in 
Future for total (treatment-naïve and -experienced) population. Sensitivity analy-
ses doubling or halving the CHC population and increasing SMV+PR MS to 15% or 
20% resulted in incremental PMPM drug-only costs of $-0.002 or $0.000 and -$0.001 
or -$0.002, respectively. cOnclusiOns: Modelled drug-only costs results suggest 
that SMV+PR adoption had an incremental impact to a U.S. health plan budget of 
-$0.001 PMPM (sensitivity analysis ranged -$0.002-$0.000 PMPM). When the base case 
considered drug costs plus outcomes, this resulted in a health plan’s total annual 
cost per SVR decrease of $2,844.
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A dyNAmIC hEAlTh ECONOmICS APP: ThE budgET ImPACT OF AdOPTINg ThE 
rECENTly FdA APPrOvEd hEPATITIS C ThErAPy, SOFOSbuvIr TO A uNITEd 
STATES FOrmulAry
Lingohr-Smith M., Lin J.
Novosys Health, Flemington, NJ, USA
Objectives: The objective of this study was to design an app to estimate the budget 
impact of the adoption of Sofosbuvir, a new antiviral hepatitis C (HCV) therapy to a 
formulary in the U.S. MethOds: The pharmacy budget impact to a formulary was 
defined as the difference between the cost “with Sofosbuvir” and the cost “without 
Sofosbuvir” for the treatment of the eligible chronically infected HCV population. 
The model takes the following into account: number of HCV infected persons, per-
cent chronically infected, percent diagnosed, percent diagnosed and treated with 
triple therapy, percent covered by insurance, and drug costs. The app may be used 
to estimate the budget impact of the adoption of Sofosbuvir to either a commercial 
or Medicare/Medicaid formulary in each state of the U.S. and in the U.S. overall and 
may be used with iPad, iPhone, other tablets, laptops, and desktops. Results: In 
2013 in the U.S., 4,008,572 persons were estimated to be chronically infected with 
HCV. At a default of 3% of those diagnosed with chronic HCV being treated with triple 
therapy, and with Sofosbuvir having 15% of the market share the total pharmacy 
budget impact was estimated at $11.3 million annually (before adoption: $1,877 
million vs. after adoption: $1,888 million) among those commercially insured in 
the US. This represents a relative increase of 0.6% ($0.005 per member per month 
(PMPM)). Among those who are Medicaid/Medicare insured the budget impact was 
estimated at $5.8 million, also a relative increase of 0.6%. cOnclusiOns: Based 
on current treatment practices of HCV infected persons, the budget impact of add-
ing Sofosbuvir to a U.S. commercial or government health plan formulary is low 
($0.005 PMPM). The impact of increasing HCV screening and treatment rate and the 
potential reduction of medical costs due to Sofosbuvir’s > 90% sustained virological 
response will require future studies.
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ECONOmIC ImPACT OF vACCINATION WITh 10-vAlENT vErSuS 13-vAlENT 
PNEumOCOCCAl CONjugATEd vACCINES IN COlOmbIA
Diaz J.A.1, Urrego Novoa J.R.1, Moreno J.A.2, Peralta Pizza F.3, Reyes Sanchez J.M.3, Brown P.4
1Facultad de Ciencias, Universidad Nacional de Colombia, Bogotá, Colombia, 2Universidad 
distrital, Bogota, Colombia, 3Universidad Nacional de Colombia, Bogotá, Colombia, 4University of 
California, CA, USA
Objectives: Infections produced by Streptococcus pneumoniae have an important 
impact on worldwide health due the high burden of disease they generate; these 
